MT Newswires Live10:05
Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Guangdong Hengrui Medicine obtained approval from China's drug regulator to begin clinical trials for SHR-7012 injection.
SHR-7012 targets cutaneous lupus erythematosus, according to a Thursday aftermarket filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
